<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547220</url>
  </required_header>
  <id_info>
    <org_study_id>SHP616-302</org_study_id>
    <nct_id>NCT02547220</nct_id>
  </id_info>
  <brief_title>A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Patients With Kidney Transplant</brief_title>
  <official_title>A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinryze® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-mediated Rejection in Kidney Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of Cinryze® given for the treatment of acute antibody-mediated
      rejection (of renal allograft) (AMR) in kidney transplant recipients as measured by the
      proportion of subjects with new or worsening transplant glomerulopathy (TG) at 6 months after
      treatment initiation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 1, 2015</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate efficacy for the treatment of acute AMR of renal allograft in kidney transplant recipients as measured by the proportion of subjects with new or worsening transplant glomerulopathy (TG) at 6 months after treatment initiation using Banff criteria</measure>
    <time_frame>Screening to Month 6</time_frame>
    <description>Administer CINRYZE with plasmapheresis, plasma exchange, or immune absorption treatments and sucrose-free immunoglobulin (IVIg).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with all-cause graft failure</measure>
    <time_frame>Screening to Month 48 (End of Study [EOS]) (+/- 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to all-cause graft failure</measure>
    <time_frame>Screening to Month 48 (EOS) (+/- 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with graft failure due to AMR</measure>
    <time_frame>Screening to Month 48 (EOS) (+/- 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal allograft function (eGFR) as calculated by the Modification of Diet in Renal Disease (MDRD formula)</measure>
    <time_frame>Screening to Month 48 (EOS) (+/- 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in histopathology at Month 6 post-treatment per Banff criteria</measure>
    <time_frame>Screening to Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first recurrence of biopsy-proven acute AMR after dosing</measure>
    <time_frame>Screening to Month 48 (EOS) (+/- 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum Cr</measure>
    <time_frame>Screening to Month 48 (EOS) (+/- 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall subject survival</measure>
    <time_frame>Screening to Month 48 (EOS) (+/- 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Screening to Month 48 (EOS) (+/- 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vital Signs (Heart Rate)</measure>
    <time_frame>Screening to Month 48 (EOS) (+/- 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vital Signs (Blood Pressure)</measure>
    <time_frame>Screening to Month 48 (EOS) (+/- 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antibodies to C1inhibitor (INH)</measure>
    <time_frame>Screening to Month 48 (EOS) (+/- 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical safety laboratory testing (Hematology)</measure>
    <time_frame>Screening to Month 48 (EOS) (+/- 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical safety laboratory testing (Serum Chemistry)</measure>
    <time_frame>Screening to Month 48 (EOS) (+/- 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical safety laboratory testing (Serum Blood urea nitrogen/Cr)</measure>
    <time_frame>Screening to Month 48 (EOS) (+/- 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to graft failure due to AMR</measure>
    <time_frame>Screening to Month 48 (EOS) (+/- 14 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Acute Antibody-Mediated Rejection (AMR)</condition>
  <arm_group>
    <arm_group_label>Cinryze®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eligible subjects with biopsy-proven AMR will be randomized (56 per arm) to receive either IV Cinryze® or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>eligible subjects with biopsy-proven AMR will be randomized (56 per arm) to receive either IV Cinryze® or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cinryze®</intervention_name>
    <description>7 doses of study drug over 13 days</description>
    <arm_group_label>Cinryze®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>7 doses of placebo over 13 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be &gt;=18 and &lt;=70 years of age.

          2. Weigh &gt;=45 kg with a body mass index (BMI) &lt;35 kg/m^2 at screening.

          3. Have HLA DSA identified at the time of diagnosis of AMR. If it is anticipated that the
             local DSA results will not be available within the screening period, previously
             obtained local DSA results can be used to assess eligibility, if obtained after kidney
             transplant and within 30 days prior to the qualifying AMR episode. In any instance, a
             local DSA test should still be performed at the time of AMR diagnosis.

          4. Have a first qualifying episode of AMR in the subject's current renal allograft
             between 72 hours and 12 months after transplant defined by a renal allograft biopsy
             demonstrating neutrophil and/or monocyte infiltration in the PTC and/or glomeruli with
             or without evidence of C4d deposition by immunohistopathology according to 2013 Banff
             criteria.

          5. Have achieved adequate renal function defined as: Pre-AMR baseline eGFRMDRD &gt;=20
             mL/min/1.72m^2 for a qualifying AMR episode occurring &lt;=21 days after transplant or
             pre-AMR baseline eGFRMDRD &gt;=30 mL/min/1.72m^2 for a qualifying AMR episode occurring
             &gt;21 days after transplant. The pre-AMR baseline is the highest eGFRMDRD value obtained
             following the kidney transplant and within 30 days prior to the qualifying AMR
             episode. If more than 1 eGFRMDRD value is available, a mean of the 2 highest values
             (at least 1 day apart and both prior to the AMR episode) will be used as the pre-AMR
             baseline value. If no eGFRMDRD was obtained within 30 days prior to biopsy, it can be
             evaluated within a 60 day period.

          6. Receive first dose of investigational product after 7 days after the kidney transplant
             procedure and within 7 days after the qualifying renal allograft biopsy procedure that
             was positive for AMR.

          7. Be informed of the nature of the study and provide written informed consent before any
             study-specific procedures are performed.

          8. If female and of child-bearing potential, must have a negative urine pregnancy test
             confirmed by a negative serum beta human chorionic gonadotropin (beta-HCG) pregnancy
             test at the Screening Visit and must have a negative urine pregnancy test at the Day 1
             visit.

          9. Agree to comply with any applicable contraceptive requirements of the protocol.

        Exclusion Criteria:

          1. Have received pediatric en bloc kidney transplant.

          2. Have focal segmental glomerulosclerosis, rapidly progressive glomerulonephritis,
             membrano-proliferative glomerulonephritis type 1,(including C3 glomerulopathy), &quot;dense
             deposit disease&quot;, or thrombotic microangiopathy as the cause of native kidney failure.

          3. Have prior or concurrent non-renal solid organ transplant or hematopoietic stem cell
             transplant (HSCT) or have more than 2 completed kidney transplant procedures.

          4. Have a known neoplastic lesion in the transplanted allograft.

          5. Have, any ongoing infection that causes hemodynamic compromise or as determined by the
             investigator, any surgical or medical condition that could interfere with the
             administration of investigational product, interpretation of study results, or could
             compromise patient safety, including (as determined by the transplanting surgeon and
             documented in the operative report) any major technical complications of the renal
             artery, renal vein, or ureteral anastomosis.

          6. Have ongoing treatment for HCV infection.

          7. Have had a recent myocardial infarction (MI) or transient ischemic attack (TIA) within
             the past 6 months.

          8. Have a history of abnormal bleeding, clotting, or any coagulopathy (excluding a
             history of clotted hemodialysis access or superficial thrombophlebitis in the absence
             of medically confirmed coagulopathy).

          9. Have a history of allergic reaction to CINRYZE or other blood products.

         10. Have had any change in androgen therapy (eg, danazol, oxandrolone, stanozolol,
             testosterone), tranexamic acid, epsilon-aminocaproic acid, or other fibrinolytics
             within 3 months before the first dose of investigational product.

         11. Have participated in the active dosing phase of any other investigational drug study
             within 30 days prior to dosing with investigational product.

         12. Have any of the following local laboratory values prior to dosing with investigational
             product:

               -  Within 24 hours prior to subject dosing, white blood cell (WBC) count &lt;0.5×10^9/L
                  or &gt;20×10^9/L (the value of &gt;20×10^9/L should be excluded if obtained during
                  steroid treatment)

               -  Within 72 hours prior to subject dosing platelet count &lt; 25×10^9/L or &gt;600×10^9/L

         13. Be pregnant or breastfeeding.

         14. Have received any of the following agents within 1 month prior to the first dose of
             investigational product:

               -  Sucrose-containing IVIg

               -  Any C1 INH (plasma-derived [eg, CINRYZE®, Berinert®, Cetor®] or recombinant [eg,
                  Rhucin®])

               -  Eculizumab (Soliris®)

               -  Ecallantide (Kalbitor®)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Study Physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <email>clinicaltransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kidney Transplant Research Office at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suphamai Bunnapradist</last_name>
      <phone>310-794-8516</phone>
    </contact>
    <investigator>
      <last_name>Suphamai Bunnapradist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keck School of Medicine at USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasir Qazi</last_name>
      <phone>323-442-5908</phone>
    </contact>
    <investigator>
      <last_name>Yasir Qazi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Webber</last_name>
      <phone>415-353-1290</phone>
    </contact>
    <investigator>
      <last_name>Allison Webber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Of Colorado School Of Medicine</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Southern</last_name>
    </contact>
    <investigator>
      <last_name>James Cooper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Gilbert</last_name>
      <phone>202-444-0991</phone>
    </contact>
    <investigator>
      <last_name>Alexander Gilbert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adela Mattiazzi</last_name>
      <phone>305-355-5241</phone>
    </contact>
    <investigator>
      <last_name>Adela Mattiazzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Transplant Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobby Nibhanapudy</last_name>
      <phone>407-303-2474</phone>
    </contact>
    <investigator>
      <last_name>Bobby Nibhanupudy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Wolf</last_name>
      <phone>404-605-2629</phone>
    </contact>
    <investigator>
      <last_name>Joshua Wolf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Firedewald</last_name>
      <phone>312-695-0338</phone>
    </contact>
    <investigator>
      <last_name>John Friedewald</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdolreza Haririan</last_name>
      <phone>410-328-3720</phone>
    </contact>
    <investigator>
      <last_name>Abdolreza Haririan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sami Alasfar</last_name>
      <phone>410-382-6853</phone>
    </contact>
    <investigator>
      <last_name>Sami Alasfar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Womens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Chandraker</last_name>
      <phone>617-732-7412</phone>
    </contact>
    <investigator>
      <last_name>Anil Chandraker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ty Dunn</last_name>
      <phone>612-625-4758</phone>
    </contact>
    <investigator>
      <last_name>Ty Dunn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Brennan</last_name>
      <phone>314-362-8351</phone>
    </contact>
    <investigator>
      <last_name>Daniel Brennan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Barnabas Medical Center</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anup Patel</last_name>
      <phone>973-322-8216</phone>
    </contact>
    <investigator>
      <last_name>Anup Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nandita Singh</last_name>
      <phone>212-241-0255</phone>
    </contact>
    <investigator>
      <last_name>Nandita Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lloyd Ratner</last_name>
      <phone>212-342-3539</phone>
    </contact>
    <investigator>
      <last_name>Lloyd Ratner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital - Weill-Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jim Kim</last_name>
      <phone>212-746-5330</phone>
    </contact>
    <investigator>
      <last_name>Jim Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Longone Medical Center</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Montgomery</last_name>
      <phone>914-949-2490</phone>
    </contact>
    <investigator>
      <last_name>Robert Montgomery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emily Renfro</last_name>
      <phone>513-584-0985</phone>
      <email>woodlees@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Ervin Woodle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Fatica</last_name>
      <phone>216-312-3050</phone>
    </contact>
    <investigator>
      <last_name>Richard Fatica</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Pelletier</last_name>
      <phone>614-293-4627</phone>
    </contact>
    <investigator>
      <last_name>Ronald Pelletier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INTEGRIS Nazih Zuhdi Transplant Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose El-Amm</last_name>
      <phone>405-949-3349</phone>
    </contact>
    <investigator>
      <last_name>Jose El-Amm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Monroeville</city>
        <state>Pennsylvania</state>
        <zip>15146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Puneet Sood</last_name>
      <phone>412-648-6048</phone>
    </contact>
    <investigator>
      <last_name>Puneet Sood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roy Bloom</last_name>
      <phone>215-662-4643</phone>
    </contact>
    <investigator>
      <last_name>Roy Bloom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Schaefer</last_name>
      <phone>615-936-0700</phone>
    </contact>
    <investigator>
      <last_name>Heidi Schaefer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor All Saints Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Fischbach</last_name>
      <phone>817-922-7667</phone>
    </contact>
    <investigator>
      <last_name>Bernard Fischbach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Gaber</last_name>
      <phone>713-441-6170</phone>
    </contact>
    <investigator>
      <last_name>Ahmed Gaber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuad Shihab</last_name>
      <phone>801-585-3823</phone>
    </contact>
    <investigator>
      <last_name>Fuad Shihab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Health Care Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Gill</last_name>
      <phone>604-806-9464</phone>
    </contact>
    <investigator>
      <last_name>John Gill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruth Sapir-Pichhadze</last_name>
      <phone>514-934-1934</phone>
    </contact>
    <investigator>
      <last_name>Ruth Sapir-Pichhadze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Blancho</last_name>
      <phone>(+)33 2 40 08 74 54</phone>
    </contact>
    <investigator>
      <last_name>Gilles Blancho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <state>Val-De-Marne</state>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Grimbert</last_name>
      <phone>+33 149812457</phone>
    </contact>
    <investigator>
      <last_name>Philippe Grimbert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Malvezzi</last_name>
      <phone>(+)33 476765517</phone>
    </contact>
    <investigator>
      <last_name>Paolo Malvezzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Durrbach</last_name>
      <phone>+33 145212722</phone>
    </contact>
    <investigator>
      <last_name>Antoine Durrbach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Glotz</last_name>
      <phone>+33 142499631</phone>
    </contact>
    <investigator>
      <last_name>Denis Glotz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Legendre</last_name>
      <phone>+33 144495432</phone>
    </contact>
    <investigator>
      <last_name>Christophe Legendre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nassim Kamar</last_name>
      <phone>+33 561323283</phone>
    </contact>
    <investigator>
      <last_name>Nassim Kamar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universität Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Sommerer</last_name>
      <phone>+49 62215635296</phone>
    </contact>
    <investigator>
      <last_name>Claudia Sommerer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Steinbach</city>
        <state>Hessen</state>
        <zip>61449</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ingeborg Hauser</last_name>
      <phone>+496963016668</phone>
    </contact>
    <investigator>
      <last_name>Ingeborg Hauser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friedrich Thaiss</last_name>
      <phone>+49 954903</phone>
    </contact>
    <investigator>
      <last_name>Friedrich Thaiss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan-Stephan Sanders</last_name>
      <phone>+31 0503616161</phone>
    </contact>
    <investigator>
      <last_name>Jan-Stephan Sanders</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.W.F. van den Hoogen</last_name>
      <phone>+31107035756</phone>
    </contact>
    <investigator>
      <last_name>M.W.F. van den Hoogen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Lauzurica</last_name>
      <phone>+34934651200</phone>
      <email>rlauzurica.germanstrias@gencat.cat</email>
    </contact>
    <investigator>
      <last_name>Ricardo Lauzurica</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Lauzurica</last_name>
      <phone>34 934 65 12 00</phone>
    </contact>
    <investigator>
      <last_name>Ricardo Lauzurica</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>8907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oriol Bestard Matamoros</last_name>
      <phone>+34 932607614</phone>
    </contact>
    <investigator>
      <last_name>Oriol Matamoros</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Perez Flores</last_name>
      <phone>+34 913303490</phone>
    </contact>
    <investigator>
      <last_name>Isabel Perez Flores</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amado Andres</last_name>
      <phone>+34913303490</phone>
    </contact>
    <investigator>
      <last_name>Amado Andres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

